Safety, efficacy, and pharmacokinetics of eratrectinib (VC004) in solid tumors with NTRK fusions: phase 1 results from a phase 1/2 study Authors: Shengyu Zhou, Changgong Zhang, Guowen Wang, Jun Qian, Gang Huang, Jiaqiang Wang, Suxia Luo, Youhua Zhu, Qingyuan Zhang, Ting Wei, Yongsheng Li, Zhendong Li, Dongyuan Zhu, Huarong Zhao, Meiyu Fang, Shoubing Zhou, Qing Xu, Yu Chen, Kejun Nan, Jiuwei Cui, Xueqiang Zhu, Yanchun Gong, Yong Wu, Xiaojuan Lai, Yuankai Shi Published: 2026 ABSTRACT BackgroundTropomyosin receptor kinases (TRK) tyrosine kinase inhibitors (TKIs) have demonstrated marked efficacy in neurotrophic receptor tyrosine kinase (NTRK) fusion positive tumors. However, resistance inevitably develops. Eratrectinib (VC004) is a next-generation selective TRK TKI which can overcome drug resistance.MethodsIn this phase 1 study, patients with locally advanced or metastatic solid tumors were enrolled in the dose-escalation part. A standard 3 + 3 design was adopted to sequentially assign patients at 25 mg twice daily (BID), 50 mg BID, 100 mg BID, and 200 mg BID dose levels of oral eratrectinib. After each dose had been established, we expanded specific dose cohorts in patients with NTRK fusion positive locally advanced or metastatic solid tumors to obtain adequate data for safety, pharmacokinetics (PK), and efficacy. The primary endpoints of this study were safety, maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D).ResultsBetween December 4, 2020 and November 4, 2021, 16 patients were enrolled in the dose-escalation part and a dose of 100 mg BID was identified as MTD. Between May 8, 2021 and March 19, 2025, 75 patients were enrolled in the dose-expansion part at doses of eratrectinib 25 mg BID, 50 mg BID, and 75 mg BID. Treatment-emergent adverse events (TEAEs) occurred in 94.7% (71/75) of patients. The most common treatment-related adverse events (TRAEs) included dizziness (51/75, 68.0%), anaemia (28/75, 37.3%), weight increased (27/75, 36.0%), hypertriglyceridemia (25/75, 33.3%). ≥ grade 3 TRAEs occurred in 17.3% (13/75) of patients. No TRAEs led to death. The dose of 50 mg BID was chosen as RP2D based on the results of safety, PK, and efficacy. At the RP2D dose, objective response rate (ORR) was 70% (21/30, 95% confidence interval 50.6–85.3).ConlusionsEratrectinib demonstrated manageable safety profile and promising efficacy in patients with NTRK fusion positive solid tumors, representing a new treatment option for this patient population. Further studies to confirm the efficacy and safety of eratrectinib are ongoing.Trial registration NCT04614740 (ClinicalTrials.gov).Supplementary InformationThe online version contains supplementary material available at https://doi.org/10.1186/s40164-026-00799-9. Background Oncogenic fusions involving the neurotrophic receptor tyrosine kinase (NTRK) genes, including NTRK1, NTRK2, and NTRK3, which resulted ligand-independent constitutive activation of the receptor kinase domain, have been identified in a wide variety of tumor types [1]. The overall prevalence of NTRK fusions was 0.26% of 33,997 patients and 0.28% of 26,312 patients with different tumors in two retrospective analyses, respectively [2, 3]. There is a much higher frequency of NTRK fusions in several rare malignancies [4]. For example, NTRK fusions were found in > 90% of patients with secretory breast carcinoma or infantile fibrosarcomas, and in 20–50% of patients with high grade glioma, congenital mesoblastic nephroma, pediatric differentiated thyroid cancer, or pleomorphic adenoma [4]. While, the NTRK fusions are present at a frequency of < 1% in most common tumor types, such as lung adenocarcinoma, colorectal cancer, breast cancer, or melanoma [2–4]. Currently, two small molecular first-generation tropomyosin receptor kinases (TRK) tyrosine kinase inhibitors (TKIs), larotrectinib and entrectinib, have been approved for the treatment of patients with NTRK fusion positive tumors by the U.S. Food and Drug Administration and the China National Medical Products Administration. In pooled analyses of phase 1/2 study, larotrectinib, a selective TRK inhibitor, demonstrated an objective response rate (ORR) of 60% (204/339, 95% confidence interval [CI] 55–65) in patients with solid tumors harboring NTRK fusion [5]. Entrectinib, summary of overall efficacy assessed by blinded independent central review in adult patients with NTRK fusion-positive solid tumors with an ORR of 59% (32/54, 95% CI 45–72) [6]. Despite the marked and durable efficacy of these two TRK TKIs, resistance inevitably develops. Kinase solvent front mutation, such as G623R, represents a significant mechanism of resistance in NTRK fusion positive tumors after larotrectinib or entrectinib treatment and mediated acquired resistance in 7 of 10 patients who had disease progression after larotrectinib treatment [7, 8]. Repotrectinib, a next-generation pan-ROS Proto-Oncogene 1, Receptor Tyrosine Kinase, TRK, Anaplastic Lymphoma Kinase TKI, potently inhibiting solvent front mutations of TRK [9], has demonstrated an ORR of 50% (24/48, 95% CI 35–65) in TRK TKI pretreated patients with locally advanced or metastatic NTRK gene fusion positive solid tumors, and 58% (23/40, 95% CI 41–73) in the TRK TKI naïve patients [10]. Eratrectinib (VC004), developed by Jiangsu Vcare Pharmatech Co, Ltd, Nanjing, China, is a next-generation selective TRK TKI demonstrated to overcome NTRK1 G595R and NTRK3 G623R solvent front mutation in pre-clinical studies (unpublished data), which is resistant to first-generation TRK TKIs in NTRK fusion positive tumors [11]. Here, we report the results of phase 1 dose-escalation and dose-expansion parts of a phase 1/2 study of eratrectinib in adult and paediatric patients with advanced solid tumors. Materials and methods Study design and patients The phase 1 of this phase 1/2 study aimed to evaluate the safety, pharmacokinetics (PK), and preliminary efficacy of eratrectinib, which included dose-escalation part and dose-expansion part. Eligible patients had histologically or cytologically confirmed solid tumors with locally advanced or metastatic disease not amenable to curative surgery or radiotherapy; life expectancy ≥ 12 weeks; had adequate organ and hematologic function; women of childbearing age require a negative pregnancy test before enrollment and contraceptive measures were required for all enrolled patients during study treatment and within 180 days after the end of study treatment. Key exclusion criteria included receipt of large-body area radiotherapy, systemic anti-tumor therapy, or major surgery within 4 weeks before first dose of study treatment; clinically significant cardiovascular disease, e.g. left ventricular ejection fraction ≤ 50%, class III/IV heart failure of New York Heart Association, or uncontrolled hypertension; any serious or uncontrolled systemic disease; gastrointestinal abnormalities that would interfere with intake, transport, or absorption of the study drug. The phase 1 dose-escalation part of this study enrolled patients lack of, failure to, intolerant of, or not amenable to standard treatment; aged ≥ 18 years; had an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1. Patients with primary central nervous system (CNS) tumors or metastasis were excluded. NTRK fusion status was not an eligibility criterion for enrollment of this part. The phase 1 dose-expansion part included 4 cohorts (Cohort A: eratrectinib 25 mg twice daily [BID], Cohort B: eratrectinib 50 mg BID, Cohort C: eratrectinib 75 mg BID, Cohort D: eratrectinib 50 mg BID), enrolled patients aged ≥ 12 years, while had a body surface area ≥ 1 m2 for patients aged 12–18 years; harboured NTRK fusions (except for Cohort D), which were confirmed at central laboratory for partial patients; had an ECOG PS ≤ 2; at least one measurable lesion (applicable to patients with NTRK fusion-positive locally advanced or metastatic solid tumors, with no such restriction for Cohort D) according to the Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1 [12] or the Response Assessment in Neuro-Oncology (RANO) criteria [13, 14]. Patients with CNS tumors or metastasis were included if they were asymptomatic or stable, not requiring steroid management, within the 7 days before study enrollment. Cohort D included patients who do not have measurable disease or those without NTRK fusions, further confirmation by central laboratory was not feasible. These patients were for exploratory and observational purposes only. This study was conducted in accordance with the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use Guideline for Good Clinical Practice and the Declaration of Helsinki. The study protocol and all amendments were approved by the independent institutional review boards or ethics committees at each participating hospital. Written informed consent was obtained from all patients before enrolment. This study was registered with ClinicalTrials.gov, NCT04614740. Procedures We used a standard 3 + 3 design to sequentially assign patients at 25 mg BID, 50 mg BID, 100 mg BID, and 200 mg BID dose levels of oral eratrectinib. The dose-escalation part started with a single-dose period in the first 3 days and followed by a multiple-dose period, in which the patients received the same dose administration in 4-week cycles, until unacceptable toxicity, disease progression, patient withdrawal, investigator’s judgement, study termination, or other treatment discontinuation criteria were met. After each dose had been established, we expanded specific dose cohorts to obtain adequate data for safety, PK, and efficacy. Safety assessments included documentation of treatment-emergent adverse events (TEAEs), treatment-related adverse events (TRAEs), treatment-emergent serious adverse events (TESAEs), treatment-related serious adverse events (TRSAEs), and vital signs, as well as findings from physical examinations, clinical laboratory tests, and cardiac function examinations. Severity of adverse events (AEs) was graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0. Dose-limiting toxicities (DLTs) were defined as grade 3 febrile neutropenia, grade 4 neutropenia, grade 4 anemia, grade 3 thrombocytopenia with bleeding, grade 4 thrombocytopenia; grade 3 or 4 non-hematological toxicities, except for fatigue, nausea, or vomiting decreased to grade 1–2 within 7 days with supportive care, included grade 3 or 4 diarrhea persisting for ≥ 24 h; any toxicities leading to study treatment discontinuation or study termination, except for disease progression. DLTs were observed during the single-dose period and the first 4 weeks of the multiple-dose period. If DLT were observed in more than 2 of up to 6 patients at a certain dose, the dose will be considered intolerable and dose escalation will be stopped. The next lower dose will be identified as the maximum tolerated dose (MTD). Blood samples were collected for PK analysis of eratrectinib at specific time points. Single-dose period of dose-escalation part: within 1 h before eratrectinib administration at cycle 0 day 1; 15 min ± 1 min, 30 min ± 1 min, 1 h ± 10 min, 2 h ± 10 min, 3 h ± 10 min, 4 h ± 10 min, 6 h ± 10 min, 8 h ± 10 min, 12 h ± 10 min, 24 h ± 1 h, 48 h ± 2 h after eratrectinib administration. Multiple-dose period of dose-escalation part: within 1 h before first dose of eratrectinib at cycle 1 day 1 and cycle 1 day 8; 15 min ± 1 min, 30 min ± 1 min, 1 h ± 10 min, 2 h ± 10 min, 3 h ± 10 min, 4 h ± 10 min, 6 h ± 10 min, 8 h ± 10 min after first dose of eratrectinib at cycle 1 day 8; within 1 h before second dose of eratrectinib at cycle 1 day 8, cycle 1 day 9, cycle 1 day 15; within 1 h before first dose of eratrectinib at cycle 2 day 1. Dose-expansion part: within 1 h before first dose of eratrectinib at cycle 1 day 1; 15 min ± 1 min, 30 min ± 1 min, 1 h ± 10 min, 2 h ± 10 min, 3 h ± 10 min, 4 h ± 10 min, 6 h ± 10 min, 8 h ± 10 min after first dose of eratrectinib at cycle 1 day 1; within 1 h before second dose of eratrectinib at cycle 1 day 1; within 1 h before first dose of eratrectinib at cycle 1 day 2 and cycle 1 day 8; 15 min ± 1 min, 30 min ± 1 min, 1 h ± 10 min, 2 h ± 10 min, 3 h ± 10 min, 4 h ± 10 min, 6 h ± 10 min, 8 h ± 10 min after first dose of eratrectinib at cycle 1 day 8; within 1 h before second dose of eratrectinib at cycle 1 day 8; within 1 h before first dose of eratrectinib at cycle 1 day 9; cycle 1 day 15, and cycle 2 day 1. Efficacy assessments were conducted in accordance with the RECIST version 1.1 or the RANO criteria, by investigators during the dose-escalation part and by independent review committee (IRC) and investigators during the dose-expansion part. Tumor response was assessed through computed tomography or magnetic resonance imaging at 8-week intervals for the first 24 cycles, and at 16-week intervals for the subsequent duration of study treatment. For patients with primary CNS tumors, response was assessed at 4-week intervals for the first 4 cycles, at 8-week intervals for cycle 5 to cycle 12, and at 12-week intervals for the subsequent duration of study treatment. Patients were followed up for safety over the first 28 days after the end of study treatment, thereafter followed up for survival at 3-month intervals. The DNA was extracted from the formalin-fixed, paraffin-embedded samples (FFPE) using the QIAamp DNA FFPE Kit (QIAGEN, Valencia, CA, USA), following the manufacturer’s instructions. The VarScan2 was used for detection of candidate somatic mutations. Single nucleotide variants (SNVs) or indels were annotated with DELLY and manually checked with the Integrative Genomics Viewer. Detailed filter criteria for tumor samples were as follows: (1) for hotspot SNV or indel: variant allele frequency (VAF) ≥ 0.5%, supporting reads ≥ 3, depth ≥ 30X, (2) for non-hotspot SNV or indel: VAF ≥ 1%, supporting reads ≥ 6, depth ≥ 30X, (3) for structural variant, reads ≥ 3. Copy number variations (CNVs) were detected using a freely available software package “CNVkit” with default parameters. Somatic CNVs were identified using paired normal/tumor samples for each exon with a cut-off of 0.6 for copy-number loss and 2.0 for copy-number gain. Endpoints For the dose-escalation part, the primary endpoints were safety and MTD of eratrectinib among patients with locally advanced or metastatic solid tumors; the secondary endpoints were PK and efficacy. For the dose-expansion part, the primary endpoints were safety and recommended phase 2 dose (RP2D) of eratrectinib among patients with locally advanced or metastatic solid tumors harbouring NTRK fusions; the secondary endpoints were PK and efficacy. PK parameters of eratrectinib included maximum concentration (Cmax), time to reach Cmax (Tmax), time to the last measurable concentration (Tlast), elimination half-life (t1/2), area under the curve of serum concentration versus time from 0 to the last measurable concentration (AUC0−last), area under the curve of serum concentration versus time from 0 to infinity (AUC0−inf), apparent total plasma clearance (CL/F)、apparent volume of distribution (Vz/F), maximum concentration at steady state (Cmax, ss), area under the curve of serum concentration versus time during dosing intervals (AUC0−tau), apparent total plasma clearance at steady state (CLss/F), average concentration at steady state (Cav, ss), minimum concentration at steady state (Cmin, ss), accumulation ratio calculated from the AUC0−tau (Rac(AUC)), accumulation ratio calculated from the Cmax (Rac(Cmax)). Efficacy assessments included ORR, disease control rate (DCR), duration of response (DoR), progression-free survival (PFS), and overall survival (OS). ORR was defined as the percentage of patients who had complete response (CR) or partial response (PR). DCR was defined as the percentage of patients who had CR, PR or stable disease (SD). DoR was defined as the time from achieving CR or PR to the first documentation of progressive disease (PD). PFS was defined as the time from the first dose of eratrectinib to the first documentation of PD or death from any cause, whichever occurred earlier. OS was defined as the time from the first dose of eratrectinib to death from any reason. Statistical analysis For the dose-escalation part, the sample size was estimated to be 12–24, according to the 3 + 3 design, based on the number of dose groups and patients occurring DLTs at each dose level. For the dose-expansion part, a total of 35–106 patients were planned for enrollment to 4 different dose cohorts based on the results of the dose-escalation part (detailed in protocol of Appendix). Safety was summarized descriptively. ORR and DCR were describe as point estimates and two-sided 95% CIs, determined by the Clopper-Pearson exact method. Survival curves and estimates of medians and rates were constructed using the Kaplan-Meier method. We used the Brookmeyer-Crowley method with a log-log function transformation to estimate 95% CIs for median times to event and the Greenwood method to estimate 95% CIs for survival rates. For DoR and PFS, data were censored at the time of last tumor assessment showing response if patients initiated new anti-tumor treatment without PD or death. The safety set (SS) included all patients who received at least one dose of eratrectinib treatment. The intention-to-treat (ITT) population included all patients who received at least one dose of eratrectinib treatment and was used for summarizing patient baseline characteristics and evaluating efficacy. The pharmacokinetic concentration set (PKCS) included all patients in the SS who had at least one serum concentration of eratrectinib. The pharmacokinetic parameter set (PKPS) included all patients in the SS who had at least one PK parameter and excluded those who had major protocol violation impacting PK parameters. All statistical analyses were performed using SAS version 9.4 (SAS Institute Inc., North Carolina, US). PK parameters were calculated using non-compartmental analysis with Phoenix software version 8.2 (Certara L.P., New Jersey, US). Results Patient characteristics Between December 4, 2020 and November 4, 2021, 19 patients were screened and 16 patients were enrolled in the dose-escalation part and received eratrectinib treatment at doses of 25 mg BID (n = 3), 50 mg BID (n = 4), 100 mg BID (n = 6), and 200 mg BID (n = 3), respectively (Fig. 1). The median age of these patients was 46.0 years (range 21–73), 75.0% (12/16) of patients were male, 100% (16/16) of patients had ECOG PS of 0–1, and 87.5% (14/16) of patients had metastatic disease. 87.5% (14/16) of patients had previous systemic therapies (Table 1). At the data cutoff date of March 19, 2025, all 16 patients in the dose-escalation part had discontinued treatment due to PD (12/16, 75.0%), patient withdrawal (1/16, 6.3%), investigator decision (1/16, 6.3%), and other reasons (2/16, 12.5%). Fig. 1Study flow diagram. # NTRK gene status was unknown. * NTRK fusion status was confirmed for 100% (5/5) of patients in the Cohort A, 96.7% (29/30) of patients in the Cohort B, 100% (2/2) of patients in the Cohort C at the central laboratory before study treatment initiation. Cohort D included patients who do not have measurable disease or those without NTRK fusions, further confirmation by central laboratory was not feasible. These patients were for exploratory and observational purposes only. BID, twice daily; NTRK, neurotrophin receptor tyrosine kinase Study flow diagram. # NTRK gene status was unknown. * NTRK fusion status was confirmed for 100% (5/5) of patients in the Cohort A, 96.7% (29/30) of patients in the Cohort B, 100% (2/2) of patients in the Cohort C at the central laboratory before study treatment initiation. Cohort D included patients who do not have measurable disease or those without NTRK fusions, further confirmation by central laboratory was not feasible. These patients were for exploratory and observational purposes only. BID, twice daily; NTRK, neurotrophin receptor tyrosine kinase Table 1Baseline Characteristics of Patients in the ITT PopulationDose-escalation partDose-expansion partTotal (N = 16)Cohort A (25 mg BID) (N = 5)Cohort B (50 mg BID) (N = 30)Cohort C (75 mg BID) (N = 2)Cohort D (50 mg BID) (N = 38)Total (N = 75)Age, years, median (range)46.0 (21, 73)52.0 (30, 73)57.0 (12, 76)52.5 (48, 57)59.0 (16, 77)57.0 (12, 77)Sex, n (%) Male12 (75.0)2 (40.0)20 (66.7)1 (50.0)22 (57.9)45 (60.0) Female4 (25.0)3 (60.0)10 (33.3)1 (50.0)16 (42.1)30 (40.0)Ethnicity, n (%) Han14 (87.5)5 (100)30 (100)2 (100)38 (100)75 (100) Others2 (12.5)00000ECOG PS, n (%) 06 (37.5)1 (20.0)7 (23.3)011 (28.9)19 (25.3) 110 (62.5)4 (80.0)22 (73.3)2 (100)23 (60.5)51 (68.0) 2001 (3.3)04 (10.5)5 (6.7)Clinical stage, n (%) II001 (3.3)001 (1.3) III1 (6.3)01 (3.3)03 (7.9)4 (5.3) IV12 (75.0)4 (80.0)28 (93.3)2 (100)33 (86.8)67 (89.3) Others3 (18.8)1 (20.0)002 (5.3)3 (4.0)Metastases sites, n (%) Brain01 (20.0)7 (23.3)010 (26.3)18 (24.0) Lung10 (62.5)2 (40.0)20 (66.7)024 (63.2)46 (61.3) Liver3 (18.8)05 (16.7)09 (23.7)14 (18.7) Bone5 (31.3)2 (40.0)12 (40.0)018 (47.4)32 (42.7) Others11 (68.8)3 (60.0)23 (76.7)1 (50.0)21 (55.3)48 (64.0)NTRK fusions, n (%)a Positive-5 (100)29 (96.7)2 (100)036 (48.0) Negative-01 (3.3)b001 (1.3)NTRK1 fusions, n (%) Positive-2 (40.0)13 (43.3)0015 (20.0) Negative-3 (60.0)17 (56.7)2 (100)022 (29.3)NTRK2 fusions, n (%) Positive-02 (6.7)002 (2.7) Negative-5 (100)27 (90.0)2 (100)034 (45.3)NTRK3 fusions, n (%) Positive-3 (60.0)14 (46.7)2 (100)019 (25.3) Negative-2 (40.0)15 (50.0)0017 (22.7) Previous systemic therapy, n (%)14 (87.5)5 (100)27 (90.0)2 (100)36 (94.7)70 (93.3)Number of previous lines of systemic therapy, n (%) 1-1 (20.0)13 (43.3)1 (50.0)13 (34.2)28 (37.3) 2-06 (20.0)012 (31.6)18 (24.0) 3-3 (60.0)7 (23.3)1 (50.0)9 (23.7)20 (26.7) Previous TRK TKI therapy, n (%)-3 (60.0)3 (10.0)2 (100)15 (39.5)23 (30.7)aHere shows the NTRK fusion data as confirmed by the central laboratory. Cohort D include patients who do not have measurable disease or those without NTRK fusions, further confirmation by central laboratory was not feasiblebOne patient was confirmed NTRK fusion-negative in the central laboratoryBID, twice daily; ECOG, Eastern Cooperative Oncology Group; ITT, intention-to-treat; NTRK, neurotrophic receptor tyrosine kinase; PS, performance status; TKI, tyrosine kinase inhibitor; TRK, tropomyosin receptor kinases Table 1Baseline Characteristics of Patients in the ITT PopulationDose-escalation partDose-expansion partTotal (N = 16)Cohort A (25 mg BID) (N = 5)Cohort B (50 mg BID) (N = 30)Cohort C (75 mg BID) (N = 2)Cohort D (50 mg BID) (N = 38)Total (N = 75)Age, years, median (range)46.0 (21, 73)52.0 (30, 73)57.0 (12, 76)52.5 (48, 57)59.0 (16, 77)57.0 (12, 77)Sex, n (%) Male12 (75.0)2 (40.0)20 (66.7)1 (50.0)22 (57.9)45 (60.0) Female4 (25.0)3 (60.0)10 (33.3)1 (50.0)16 (42.1)30 (40.0)Ethnicity, n (%) Han14 (87.5)5 (100)30 (100)2 (100)38 (100)75 (100) Others2 (12.5)00000ECOG PS, n (%) 06 (37.5)1 (20.0)7 (23.3)011 (28.9)19 (25.3) 110 (62.5)4 (80.0)22 (73.3)2 (100)23 (60.5)51 (68.0) 2001 (3.3)04 (10.5)5 (6.7)Clinical stage, n (%) II001 (3.3)001 (1.3) III1 (6.3)01 (3.3)03 (7.9)4 (5.3) IV12 (75.0)4 (80.0)28 (93.3)2 (100)33 (86.8)67 (89.3) Others3 (18.8)1 (20.0)002 (5.3)3 (4.0)Metastases sites, n (%) Brain01 (20.0)7 (23.3)010 (26.3)18 (24.0) Lung10 (62.5)2 (40.0)20 (66.7)024 (63.2)46 (61.3) Liver3 (18.8)05 (16.7)09 (23.7)14 (18.7) Bone5 (31.3)2 (40.0)12 (40.0)018 (47.4)32 (42.7) Others11 (68.8)3 (60.0)23 (76.7)1 (50.0)21 (55.3)48 (64.0)NTRK fusions, n (%)a Positive-5 (100)29 (96.7)2 (100)036 (48.0) Negative-01 (3.3)b001 (1.3)NTRK1 fusions, n (%) Positive-2 (40.0)13 (43.3)0015 (20.0) Negative-3 (60.0)17 (56.7)2 (100)022 (29.3)NTRK2 fusions, n (%) Positive-02 (6.7)002 (2.7) Negative-5 (100)27 (90.0)2 (100)034 (45.3)NTRK3 fusions, n (%) Positive-3 (60.0)14 (46.7)2 (100)019 (25.3) Negative-2 (40.0)15 (50.0)0017 (22.7) Previous systemic therapy, n (%)14 (87.5)5 (100)27 (90.0)2 (100)36 (94.7)70 (93.3)Number of previous lines of systemic therapy, n (%) 1-1 (20.0)13 (43.3)1 (50.0)13 (34.2)28 (37.3) 2-06 (20.0)012 (31.6)18 (24.0) 3-3 (60.0)7 (23.3)1 (50.0)9 (23.7)20 (26.7) Previous TRK TKI therapy, n (%)-3 (60.0)3 (10.0)2 (100)15 (39.5)23 (30.7)aHere shows the NTRK fusion data as confirmed by the central laboratory. Cohort D include patients who do not have measurable disease or those without NTRK fusions, further confirmation by central laboratory was not feasiblebOne patient was confirmed NTRK fusion-negative in the central laboratoryBID, twice daily; ECOG, Eastern Cooperative Oncology Group; ITT, intention-to-treat; NTRK, neurotrophic receptor tyrosine kinase; PS, performance status; TKI, tyrosine kinase inhibitor; TRK, tropomyosin receptor kinases Baseline Characteristics of Patients in the ITT Population aHere shows the NTRK fusion data as confirmed by the central laboratory. Cohort D include patients who do not have measurable disease or those without NTRK fusions, further confirmation by central laboratory was not feasible bOne patient was confirmed NTRK fusion-negative in the central laboratory BID, twice daily; ECOG, Eastern Cooperative Oncology Group; ITT, intention-to-treat; NTRK, neurotrophic receptor tyrosine kinase; PS, performance status; TKI, tyrosine kinase inhibitor; TRK, tropomyosin receptor kinases Between May 8, 2021 and March 19, 2025, 140 patients were screened and 76 patients were enrolled in the dose-expansion part: 5 in Cohort A, eratrectinib 25 mg BID; 30 in Cohort B, eratrectinib 50 mg BID; 2 in Cohort C, eratrectinib 75 mg BID; 39 in Cohort D, eratrectinib 50 mg BID. Among these patients, NTRK fusion status was confirmed for 100% (5/5) of patients in the Cohort A, 96.7% (29/30) of patients in the Cohort B, 100% (2/2) of patients in the Cohort C. One patient in the Cohort D had not initiated the study treatment at the data cutoff date of March 19, 2025 and was excluded from the ITT population (Fig. 1). The median age of these patients was 57.0 years (range 12–77), 60.0% (45/75) of patients were male, 93.3% (70/75) of patients had ECOG PS of 0–1, and 84.0% (63/75) of patients had metastatic disease. Patients were diagnosed with a wide range of solid tumors, among which predominant tumor types were lung cancer (53.3%, 40/75), soft tissue sarcoma (14.7%, 11/75), colorectal cancer (9.3%, 7/75), and salivary gland tumor (8.0%, 6/75). 93.3% (70/75) of patients had previously received systemic treatment, including 30.7% (23/75) of patients had previously received TRK TKIs treatment (Table 1). At the data cutoff date of March 19, 2025, 55.3% (42/75) of patients in the dose-expansion part had discontinued treatment due to PD (33/75, 43.4%), AEs (1/75, 1.3%), death (1/75, 1.3%), and other reasons (7/75, 9.2%). Safety All 3 patients receiving eratrectinib 200 mg BID occurred DLTs during dose-escalation part. Therefore, a dose of 100 mg BID was identified as MTD. For the dose-expansion part, any grade TEAEs occurred in 94.7% (71/75) of patients and any grade TRAEs occurred in 94.7% (71/75) of patients (Table 2, Table S1, and Table S2). The most common any grade TRAEs included dizziness (51/75, 68.0%), anaemia (28/75, 37.3%), weight increased (27/75, 36.0%), hypertriglyceridemia (25/75, 33.3%), hypercholesterolemia (22/75, 29.3%), aspartate aminotransferase (AST) increased (20/75, 26.7%), hyperuricaemia (19/75, 25.3%), and alanine aminotransferase (ALT) increased (18/75, 24.0%) (Table 2). ≥ grade 3 TEAEs occurred in 32.0% (24/75) of patients and ≥ grade 3 TRAEs occurred in 17.3% (13/75) of patients. ≥ grade 3 TRAEs included: dizziness (2/75, 2.7%), paresthesia (1/75, 1.3%), weight increased (2/75, 2.7%), blood creatine phosphokinase increased (1/75, 1.3%), platelet count decreased (1/75, 1.3%), hypertriglyceridemia (4/75, 5.3%), hyperuricemia (1/75, 1.3%), decreased appetite (1/75, 1.3%), anemia (3/75, 4.0%), asthenia (1/75, 1.3%), pyrexia (2/75, 2.7%), infectious pneumonia (1/75, 1.3%), and shock (1/75, 1.3%). TESAEs occurred in 22.7% (17/75) of patients and TRSAEs occurred in 8.0% (6/75) of patients. The incidence of TEAEs and TRAEs leading to dose reduction was 2.7% (2/75) for both. The incidence of TEAEs and TRAEs leading to treatment discontinuation was 4.0% (3/75) and 2.7% (2/75), respectively. TRAEs leading to dose reduction included: hyperglycemia (1/75, 1.3%), hepatic steatosis (1/75, 1.3%), ALT increased (1/75, 1.3%), AST increased (1/75, 1.3%), dizziness (1/75, 1.3%), and hallucination (1/75, 1.3%). TRAEs leading to treatment discontinuation included: dizziness (1/75, 1.3%) and shock (1/75, 1.3%). AEs leading to death occurred in 4.0% (3/75) of patients, while none was related to study treatment (Table S1). Table 2Summary of TRAEs in the SSDose-escalation partDose-expansion partTotal (N = 16)Cohort A (25 mg BID) (N = 5)Cohort B (50 mg BID) (N = 30)Cohort C (75 mg BID) (N = 2)Cohort D (50 mg BID) (N = 38)Total(N = 75)TRAEs15 (93.8)5 (100)30 (100)2 (100)34 (89.5)71 (94.7)Dizziness12 (75.0)2 (40.0)22 (73.3)2 (100)25 (65.8)51 (68.0)Anaemia8 (50.0)1 (20.0)10 (33.3)1 (50.0)16 (42.1)28 (37.3)Weight increased4 (25.0)2 (40.0)20 (66.7)05 (13.2)27 (36.0)Hypertriglyceridemia6 (37.5)2 (40.0)13 (43.3)2 (100)8 (21.1)25 (33.3)Hypercholesterolemia2 (12.5)4 (80.0)12 (40.0)1 (50.0)5 (13.2)22 (29.3)AST increased5 (31.3)011 (36.7)2 (100)7 (18.4)20 (26.7)Hyperuricaemia2 (12.5)1 (20.0)11 (36.7)1 (50.0)6 (15.8)19 (25.3)ALT increased4 (25.0)1 (20.0)10 (33.3)1 (50.0)6 (15.8)18 (24.0)Constipation4 (25.0)1 (20.0)7 (23.3)05 (13.2)13 (17.3)ALP increased008 (26.7)04 (10.5)12 (16.0)Weak005 (16.7)05 (13.2)10 (13.3)QT interval prolonged1 (6.3)07 (23.3)02 (5.3)9 (12.0)Blood creatinine increased3 (18.8)1 (20.0)5 (16.7)1 (50.0)2 (5.3)9 (12.0)Blood LDH increased1 (6.3)1 (20.0)3 (10.0)1 (50.0)3 (7.9)8 (10.7)Hyperglycemia1 (6.3)1 (20.0)4 (13.3)2 (100)1 (2.6)8 (10.7)Data are n (%)ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BID, twice daily; LDH, lactate dehydrogenase; SS, safety set; TRAEs, treatment-related adverse events Table 2Summary of TRAEs in the SSDose-escalation partDose-expansion partTotal (N = 16)Cohort A (25 mg BID) (N = 5)Cohort B (50 mg BID) (N = 30)Cohort C (75 mg BID) (N = 2)Cohort D (50 mg BID) (N = 38)Total(N = 75)TRAEs15 (93.8)5 (100)30 (100)2 (100)34 (89.5)71 (94.7)Dizziness12 (75.0)2 (40.0)22 (73.3)2 (100)25 (65.8)51 (68.0)Anaemia8 (50.0)1 (20.0)10 (33.3)1 (50.0)16 (42.1)28 (37.3)Weight increased4 (25.0)2 (40.0)20 (66.7)05 (13.2)27 (36.0)Hypertriglyceridemia6 (37.5)2 (40.0)13 (43.3)2 (100)8 (21.1)25 (33.3)Hypercholesterolemia2 (12.5)4 (80.0)12 (40.0)1 (50.0)5 (13.2)22 (29.3)AST increased5 (31.3)011 (36.7)2 (100)7 (18.4)20 (26.7)Hyperuricaemia2 (12.5)1 (20.0)11 (36.7)1 (50.0)6 (15.8)19 (25.3)ALT increased4 (25.0)1 (20.0)10 (33.3)1 (50.0)6 (15.8)18 (24.0)Constipation4 (25.0)1 (20.0)7 (23.3)05 (13.2)13 (17.3)ALP increased008 (26.7)04 (10.5)12 (16.0)Weak005 (16.7)05 (13.2)10 (13.3)QT interval prolonged1 (6.3)07 (23.3)02 (5.3)9 (12.0)Blood creatinine increased3 (18.8)1 (20.0)5 (16.7)1 (50.0)2 (5.3)9 (12.0)Blood LDH increased1 (6.3)1 (20.0)3 (10.0)1 (50.0)3 (7.9)8 (10.7)Hyperglycemia1 (6.3)1 (20.0)4 (13.3)2 (100)1 (2.6)8 (10.7)Data are n (%)ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BID, twice daily; LDH, lactate dehydrogenase; SS, safety set; TRAEs, treatment-related adverse events Summary of TRAEs in the SS Data are n (%) ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BID, twice daily; LDH, lactate dehydrogenase; SS, safety set; TRAEs, treatment-related adverse events Pharmacokinetics There was a considerable individual variability in plasma exposure of eratrectinib, with coefficients of variation ranging from 17.3% to 50.7% for Cmax and from 14.2% to 56.3% for AUC0−last (Table 3). The results of dose-exposure analysis indicated non-linear PK characteristics of eratrectinib within the studied dose range (Table S3, S4). Eratrectinib was rapidly absorbed with peak plasma concentrations occurring 1.00–2.49 h after single- or multiple-dose administration in the fasting state (Table 3). Eratrectinib showed a rapid elimination from plasma with mean t1/2 range of 2.29–4.42 h across the 25 mg, 50 mg, 75 mg, 100 mg, and 200 mg doses (Table 3; Fig. 2). There was no significant accumulation after continuous administration of eratrectinib, and the trough plasma concentration of eratrectinib tended to stabilize after 8 days of administration. Table 3PK parameters of eratrectinib in the PKPSCmax/Cmax, ss, g/mL, mean (CV)Tmax, h, median (min, max)t1/2, h, mean (CV)Tlast, h, median (min, max)AUC0−last, ng·h/mL, mean (CV)AUC0−tau, ng·h/mL, mean (CV)Single dose administration in the dose-escalation part 25 mg (N = 3)n333333statistic137 (23.1%)2.03 (1.00, 2.97)3.66 (38.3%)11.08 (11.00, 23.68)716 (56.3%)675 (40.5%) 50 mg (N = 4)n444444statistic521 (21.1%)1.51 (1.00, 2.93)4.42 (32.5%)23.83 (11.98, 24.50)2506 (46.9%)2198 (37.2%) 100 mg (N = 6)n666666statistic934 (20.7%)1.52 (1.00, 3.03)4.06 (20.0%)23.88 (23.00, 23.97)4263 (15.3%)3858 (14.0%) 200 mg (N = 3)n333333statistic2073 (17.3%)2.00 (1.98, 2.00)3.00 (24.1%)23.97 (11.98, 24.00)8618 (54.5%)8193 (48.1%)Multiple dose administration in the dose-escalation part 25 mg (N = 3)n333333statistic194 (46.7%)1.00 (0.92, 3.00)3.56 (30.7%)11.05 (11.00, 12.02)744 (36.6%)754 (35.6%) 50 mg (N = 4)n443443statistic596 (26.8%)1.50 (0.48, 2.98)3.90 (10.9%)11.28 (11.05, 11.32)2969 (31.6%)2640 (17.3%) 100 mg (N = 6)n665445statistic948 (30.4%)2.00 (1.00, 6.03)3.16 (18.2%)11.90 (11.42, 11.98)4538 (14.2%)4176 (23.1%) 200 mg (N = 3)n332333statistic1863 (37.8%)2.00 (1.98, 2.00)2.29 (2.16, 2.42)11.95 (11.33, 11.97)8254 (28.6%)8277 (29.0%)Single dose administration in the dose-expansion part 25 mg (N = 5)n555555statistic267 (22.2%)1.05 (0.52, 3.02)3.03 (16.2%)11.30 (11.02, 12.00)1099 (34.8%)1115 (35.5%) 50 mg (N = 67)n666660555560statistic483 (43.7%)1.50 (0.25, 6.07)2.90 (19.2%)11.25 (11.00, 12.00)1958 (35.4%)1890 (33.4%) 75 mg (N = 2)n222222statistic628 (593, 663)1.99 (1.98, 2.00)3.09 (2.66, 3.52)11.37 (11.00, 11.73)3148 (2981, 3316)3193 (3002, 3384)Multiple dose administration in the dose-expansion part 25 mg (N = 5)n555555statistic235 (50.7%)2.00 (1.03, 4.02)3.53 (7.9%)11.20 (11.02, 11.98)1216 (39.0%)1235 (39.9%) 50 mg (N = 67)n636360585860statistic481 (32.2%)1.92 (0.48, 6.02)3.07 (17.3%)11.18 (11.00, 12.03)1981 (28.1%)2042 (27.5%) 75 mg (N = 2)n222222statistic728 (558, 898)2.49 (2.05, 2.92)3.22 (2.90, 3.54)11.66 (11.52, 11.80)3430 (2933, 3926)3459 (2978, 3940)Cmax/Cmax, ss, t1/2, AUC0−last, and AUC0−last, are displayed as geometric mean (geometric CV%) when n ≥ 3, and arithmetic mean (min, max) when n = 2N, number of patients; n, number of patients included in descriptive statisticsAUC0−last, area under the curve of serum concentration versus time from 0 to the last measurable concentration; AUC0−tau, area under the curve of serum concentration versus time during dosing intervals; Cmax, maximum concentration; Cmax, ss, maximum concentration at steady state; CV, coefficient of variation; min, minimum; max, maximum; t1/2, elimination half-life; PK, pharmacokinetics; PKPS, pharmacokinetic parameter set; Tmax, time to reach Cmax; Tlast, time to the last measurable concentration Table 3PK parameters of eratrectinib in the PKPSCmax/Cmax, ss, g/mL, mean (CV)Tmax, h, median (min, max)t1/2, h, mean (CV)Tlast, h, median (min, max)AUC0−last, ng·h/mL, mean (CV)AUC0−tau, ng·h/mL, mean (CV)Single dose administration in the dose-escalation part 25 mg (N = 3)n333333statistic137 (23.1%)2.03 (1.00, 2.97)3.66 (38.3%)11.08 (11.00, 23.68)716 (56.3%)675 (40.5%) 50 mg (N = 4)n444444statistic521 (21.1%)1.51 (1.00, 2.93)4.42 (32.5%)23.83 (11.98, 24.50)2506 (46.9%)2198 (37.2%) 100 mg (N = 6)n666666statistic934 (20.7%)1.52 (1.00, 3.03)4.06 (20.0%)23.88 (23.00, 23.97)4263 (15.3%)3858 (14.0%) 200 mg (N = 3)n333333statistic2073 (17.3%)2.00 (1.98, 2.00)3.00 (24.1%)23.97 (11.98, 24.00)8618 (54.5%)8193 (48.1%)Multiple dose administration in the dose-escalation part 25 mg (N = 3)n333333statistic194 (46.7%)1.00 (0.92, 3.00)3.56 (30.7%)11.05 (11.00, 12.02)744 (36.6%)754 (35.6%) 50 mg (N = 4)n443443statistic596 (26.8%)1.50 (0.48, 2.98)3.90 (10.9%)11.28 (11.05, 11.32)2969 (31.6%)2640 (17.3%) 100 mg (N = 6)n665445statistic948 (30.4%)2.00 (1.00, 6.03)3.16 (18.2%)11.90 (11.42, 11.98)4538 (14.2%)4176 (23.1%) 200 mg (N = 3)n332333statistic1863 (37.8%)2.00 (1.98, 2.00)2.29 (2.16, 2.42)11.95 (11.33, 11.97)8254 (28.6%)8277 (29.0%)Single dose administration in the dose-expansion part 25 mg (N = 5)n555555statistic267 (22.2%)1.05 (0.52, 3.02)3.03 (16.2%)11.30 (11.02, 12.00)1099 (34.8%)1115 (35.5%) 50 mg (N = 67)n666660555560statistic483 (43.7%)1.50 (0.25, 6.07)2.90 (19.2%)11.25 (11.00, 12.00)1958 (35.4%)1890 (33.4%) 75 mg (N = 2)n222222statistic628 (593, 663)1.99 (1.98, 2.00)3.09 (2.66, 3.52)11.37 (11.00, 11.73)3148 (2981, 3316)3193 (3002, 3384)Multiple dose administration in the dose-expansion part 25 mg (N = 5)n555555statistic235 (50.7%)2.00 (1.03, 4.02)3.53 (7.9%)11.20 (11.02, 11.98)1216 (39.0%)1235 (39.9%) 50 mg (N = 67)n636360585860statistic481 (32.2%)1.92 (0.48, 6.02)3.07 (17.3%)11.18 (11.00, 12.03)1981 (28.1%)2042 (27.5%) 75 mg (N = 2)n222222statistic728 (558, 898)2.49 (2.05, 2.92)3.22 (2.90, 3.54)11.66 (11.52, 11.80)3430 (2933, 3926)3459 (2978, 3940)Cmax/Cmax, ss, t1/2, AUC0−last, and AUC0−last, are displayed as geometric mean (geometric CV%) when n ≥ 3, and arithmetic mean (min, max) when n = 2N, number of patients; n, number of patients included in descriptive statisticsAUC0−last, area under the curve of serum concentration versus time from 0 to the last measurable concentration; AUC0−tau, area under the curve of serum concentration versus time during dosing intervals; Cmax, maximum concentration; Cmax, ss, maximum concentration at steady state; CV, coefficient of variation; min, minimum; max, maximum; t1/2, elimination half-life; PK, pharmacokinetics; PKPS, pharmacokinetic parameter set; Tmax, time to reach Cmax; Tlast, time to the last measurable concentration PK parameters of eratrectinib in the PKPS Cmax/Cmax, ss, t1/2, AUC0−last, and AUC0−last, are displayed as geometric mean (geometric CV%) when n ≥ 3, and arithmetic mean (min, max) when n = 2 N, number of patients; n, number of patients included in descriptive statistics AUC0−last, area under the curve of serum concentration versus time from 0 to the last measurable concentration; AUC0−tau, area under the curve of serum concentration versus time during dosing intervals; Cmax, maximum concentration; Cmax, ss, maximum concentration at steady state; CV, coefficient of variation; min, minimum; max, maximum; t1/2, elimination half-life; PK, pharmacokinetics; PKPS, pharmacokinetic parameter set; Tmax, time to reach Cmax; Tlast, time to the last measurable concentration Fig. 2Mean concentration–time curves for eratrectinib. A. After single-dose administration on Cycle 0, Days 1–3 in the dose-escalation part; B. After multiple-dose administration on Cycle 1, Day 1 in the dose-escalation part; C. After single-dose administration on Cycle 1, Day 1 in the dose-expansion part; D. After multiple-dose administration on Cycle 1, Day 1 in the dose-expansion part. BID, twice daily Mean concentration–time curves for eratrectinib. A. After single-dose administration on Cycle 0, Days 1–3 in the dose-escalation part; B. After multiple-dose administration on Cycle 1, Day 1 in the dose-escalation part; C. After single-dose administration on Cycle 1, Day 1 in the dose-expansion part; D. After multiple-dose administration on Cycle 1, Day 1 in the dose-expansion part. BID, twice daily Efficacy For dose-escalation part, no patient had objective response, as NTRK fusions were not a mandatory criterion for enrollment. For dose-expansion part, efficacy analyses were performed in patients with NTRK fusion-positive solid tumors from Cohort A (25 mg BID), Cohort B (50 mg BID), and Cohort C (75 mg BID). The corresponding ORR was 40.0% (2/5, 95% CI 5.3–85.3), 70.0% (21/30, 95% CI 50.6–85.3), and 100% (2/2, 95% CI 15.8–100), respectively, assessed by IRC (Fig. 3A; Table 4). The corresponding DCRs were 80.0% (4/5, 95% CI 28.4–99.5), 83.3% (25/30, 95% CI 65.3–94.4), 100% (2/2, and 95% CI 15.8–100), respectively, assessed by IRC (Fig. 3B; Table 4). As of the data cutoff date of March 19, 2025, median follow-up time was 16.9 months (95% CI 8.8–19.3). The corresponding median DoRs were 9.2 months (95% CI not estimable [NE]-NE), NE (95% CI 21.06-NE), and 11.1 months (95% CI NE-NE), respectively (Fig. 3C, D; Table 4). The corresponding median PFS values were 11.1 months (95% CI 2.04-NE), NE (95% CI 29.34-NE), and 13.0 months (95% CI NE-NE), respectively (Fig. 3E; Table 4). The corresponding median OS values were 19.6 months (95% CI 18.76-NE), 40.7 (95% CI 31.54-NE), and NE (95% CI NE-NE), respectively (Fig. 3F; Table 4). Efficacy was consistent with investigator assessments (Table S5). The ORR in Cohort D was 2.6% (1/38; 95% CI 0-13.8), which was considered attributable to the absence of NTRK fusions in these patients. Fig. 3Efficacy in the Dose-Expansion Part Assessed by IRC. A. Waterfall plot of best percentage change from baseline in the sum of target lesions, assessed by IRC. The dashed lines at 20% and − 30% indicate the thresholds for PD and PR. B. Spider plot of percentage change from baseline in the sum of target lesions, assessed by IRC. The dashed lines at 20% and − 30% indicate the thresholds for PD and PR. C. Swimmer plot of treatment duration and tumor response assessed by IRC. D. The Kaplan-Meier curve of DoR. E. The Kaplan-Meier curve of PFS. F. The Kaplan-Meier curve of OS. BID, twice daily; CI, confidence interval; CR, complete response; DoR, duration of response; IRC, independent review committee; mDoR, median duration of response; mPFS, median progression-free survival; mOS, median overall survival; NE, not estimable; NTRK, neurotrophin receptor tyrosine kinase; ORR, objective response rate; OS, overall survival; PD, progressive disease; PFS, progression-free survival; PR, partial response A Efficacy in the Dose-Expansion Part Assessed by IRC. A. Waterfall plot of best percentage change from baseline in the sum of target lesions, assessed by IRC. The dashed lines at 20% and − 30% indicate the thresholds for PD and PR. B. Spider plot of percentage change from baseline in the sum of target lesions, assessed by IRC. The dashed lines at 20% and − 30% indicate the thresholds for PD and PR. C. Swimmer plot of treatment duration and tumor response assessed by IRC. D. The Kaplan-Meier curve of DoR. E. The Kaplan-Meier curve of PFS. F. The Kaplan-Meier curve of OS. BID, twice daily; CI, confidence interval; CR, complete response; DoR, duration of response; IRC, independent review committee; mDoR, median duration of response; mPFS, median progression-free survival; mOS, median overall survival; NE, not estimable; NTRK, neurotrophin receptor tyrosine kinase; ORR, objective response rate; OS, overall survival; PD, progressive disease; PFS, progression-free survival; PR, partial response A Table 4Efficacy assessed by IRC in the ITT PopulationDose-expansion partCohort A (25 mg BID) (N = 5)Cohort B (50 mg BID) (N = 30)Cohort C (75 mg BID) (N = 2)Cohort D (50 mg BID) (N = 38)BOR, n (%) CR01 (3.3)00 PR2 (40.0)20 (66.7)2 (100)1 (2.6) SD2 (40.0)4 (13.3)014 (36.8) Non-CR/Non-PD0001 (2.6) PD1 (20.0)4 (13.3)012 (31.6) Unevaluable01 (3.3)00 Missing00010 (26.3) ORR, % (95% CI)2 (40.0)21 (70.0)2 (100)1 (2.6)(5.27, 85.34)(50.60, 85.27)(15.81, 100)(0.07, 13.81) DCR, % (95% CI)4 (80.0)25 (83.3)2 (100)16 (42.1)(28.36, 99.49)(65.28, 94.36)(15.81, 100)(26.31, 59.18)DoR Median, months (95% CI)9.2 (NE, NE)NE (21.06, NE)11.1 (NE, NE)NE (NE, NE) 6-month rate, % (95% CI)100 (100, 100)90.5 (67.00, 97.53)100 (100, 100)NE (NE, NE) 12-month rate, % (95% CI)0 (NE, NE)90.5 (67.00, 97.53)0 (NE, NE)NE (NE, NE)PFS Median, months (95% CI)11.1 (2.04, NE)NE (29.34, NE)13.0 (NE, NE)1.9 (1.84, 7.33) 6-month rate, % (95% CI)60.0 (12.57, 88.18)81.9 (61.82, 92.07)100 (100, 100)35.0 (14.24, 56.86) 12-month rate, % (95% CI)30.0 (1.23, 71.92)78.0 (57.38, 89.50)100 (100, 100)NE (NE, NE)OS Median, months (95% CI)19.6 (18.76, NE)40.7 (31.54, NE)NE (NE, NE)NE (5.85, NE) 6-month rate, % (95% CI)100 (100, 100)96.7 (78.61, 99.52)100 (100, 100)63.2 (37.07, 80.90) 12-month rate, % (95% CI)100 (100, 100)90.0 (72.12, 96.66)100 (100, 100)NE (NE, NE)BID, twice daily; BOR, best overall response; CI, confidence interval; CR, complete response; DCR, disease control rate; DoR, duration of response; IRC, independent review committee; ITT, intention-to-treat; NE, not estimable; ORR, objective response rate; OS, overall survival; PD, progressive disease; PFS, progression-free survival; PR, partial response; SD, stable disease Table 4Efficacy assessed by IRC in the ITT PopulationDose-expansion partCohort A (25 mg BID) (N = 5)Cohort B (50 mg BID) (N = 30)Cohort C (75 mg BID) (N = 2)Cohort D (50 mg BID) (N = 38)BOR, n (%) CR01 (3.3)00 PR2 (40.0)20 (66.7)2 (100)1 (2.6) SD2 (40.0)4 (13.3)014 (36.8) Non-CR/Non-PD0001 (2.6) PD1 (20.0)4 (13.3)012 (31.6) Unevaluable01 (3.3)00 Missing00010 (26.3) ORR, % (95% CI)2 (40.0)21 (70.0)2 (100)1 (2.6)(5.27, 85.34)(50.60, 85.27)(15.81, 100)(0.07, 13.81) DCR, % (95% CI)4 (80.0)25 (83.3)2 (100)16 (42.1)(28.36, 99.49)(65.28, 94.36)(15.81, 100)(26.31, 59.18)DoR Median, months (95% CI)9.2 (NE, NE)NE (21.06, NE)11.1 (NE, NE)NE (NE, NE) 6-month rate, % (95% CI)100 (100, 100)90.5 (67.00, 97.53)100 (100, 100)NE (NE, NE) 12-month rate, % (95% CI)0 (NE, NE)90.5 (67.00, 97.53)0 (NE, NE)NE (NE, NE)PFS Median, months (95% CI)11.1 (2.04, NE)NE (29.34, NE)13.0 (NE, NE)1.9 (1.84, 7.33) 6-month rate, % (95% CI)60.0 (12.57, 88.18)81.9 (61.82, 92.07)100 (100, 100)35.0 (14.24, 56.86) 12-month rate, % (95% CI)30.0 (1.23, 71.92)78.0 (57.38, 89.50)100 (100, 100)NE (NE, NE)OS Median, months (95% CI)19.6 (18.76, NE)40.7 (31.54, NE)NE (NE, NE)NE (5.85, NE) 6-month rate, % (95% CI)100 (100, 100)96.7 (78.61, 99.52)100 (100, 100)63.2 (37.07, 80.90) 12-month rate, % (95% CI)100 (100, 100)90.0 (72.12, 96.66)100 (100, 100)NE (NE, NE)BID, twice daily; BOR, best overall response; CI, confidence interval; CR, complete response; DCR, disease control rate; DoR, duration of response; IRC, independent review committee; ITT, intention-to-treat; NE, not estimable; ORR, objective response rate; OS, overall survival; PD, progressive disease; PFS, progression-free survival; PR, partial response; SD, stable disease Efficacy assessed by IRC in the ITT Population BID, twice daily; BOR, best overall response; CI, confidence interval; CR, complete response; DCR, disease control rate; DoR, duration of response; IRC, independent review committee; ITT, intention-to-treat; NE, not estimable; ORR, objective response rate; OS, overall survival; PD, progressive disease; PFS, progression-free survival; PR, partial response; SD, stable disease Recommended phase 2 dose The RP2D of 50 mg BID was chosen on the basis of safety, PK, and efficacy results. The rationale for selection of RP2D is as follows: A total of 46 patients with locally advanced or metastatic solid tumors were enrolled in the Phase 1 dose-escalation and dose-expansion parts. The results of PK data analysis are as follows: The mean trough concentration in the 25 mg BID eratrectinib cohort exceeded the plasma concentration corresponding to the preclinical inhibitory concentration (IC)50 (6.18 ng/mL) for inhibition of NTRK-related kinases. The mean trough concentration in the 50 mg BID cohort exceeded the plasma concentration corresponding to the preclinical IC90 (55.6 ng/mL). Exposure-safety analysis revealed no significant correlation between eratrectinib exposure and the severity of TEAEs or TRAEs across the dose range of 25 mg BID to 200 mg BID. Safety results were as follows: Four dose levels were investigated: 25 mg BID, 50 mg BID, 100 mg BID, and 200 mg BID, DLTs were observed in the 200 mg BID cohort, so 100 mg BID was established as the MTD in this study. The majority of TRAEs across all cohorts were grade 1–2, indicating a favorable safety and tolerability profile. Efficacy results demonstrated that the 25 mg BID cohort showed a trend of clinical benefit with an ORR of 40.0% (2/5, 95% CI 5.3–85.3) and a DCR of 80.0% (4/5, 95% CI 28.4–99.5), the 50 mg BID cohort showed efficacy with an ORR of 70.0% (21/30, 95% CI 50.6–85.3) and a DCR of 83.3% (25/30, 95% CI 65.3–94.4). Median DoR and median PFS had not been reached, indicating substantial clinical benefit. In addition, the 75 mg BID cohort was associated with a higher incidence of dizziness. Based on comprehensive assessment of PK, safety, and efficacy data, 50 mg BID was decided as the RP2D for eratrectinib. Discussion The results of the phase 1 dose-escalation part and dose-expansion part of this phase 1/2 study demonstrated that eratrectinib, given at a dose of 50 mg BID, is safe and effective in patients with NTRK fusion-positive advanced solid tumors. Eratrectinib was generally well-tolerated with manageable AEs during the dose-expansion part. The majority of TRAEs were grade 1 or 2 in severity, with incidence of ≥ grade 3 TRAEs at 17.3% (13/75), and most were reversible with treatment interruption and/or dose modification. Dose reduction and treatment discontinuation were required in only 2.7% (2/75) and 4.0% (3/75) of patients, respectively. Although 3 patients discontinued study treatment because of AEs in this study, only 2 patients were related to study treatment. Dizziness and weight increase are unique on-target AEs of TRK TKIs [15]. Next-generation TRK TKIs showed a relatively higher incidence of dizziness compared to first-generation TRK TKIs. Dizziness occurred in 68.0% (51/75) of patients with NTRK fusion-positive advanced solid tumors who received at least once eratrectinib, and in 62% (264/422) of patients with advanced solid tumors who received repotrectinib 160 mg once daily [16]. In contrast, the incidence of dizziness was 25% (66/260) and 26.9% (168/626) for larotrectinib and entrectinib, respectively, in patients with advanced solid tumors who received at least one dose of larotrectinib or entrectinib [5, 6]. While there was no obvious difference for incidence of weight increase between first-generation and next-generation TRK TKIs, which was 11% (28/260), 27.3% (171/626), 36.0% (27/75), and 16% (67/422) for larotrectinib [5], entrectinib [6], eratrectinib, and repotrectinib [16], respectively. Eratrectinib demonstrated promising efficacy at the dose of 50 mg BID in patients with NTRK fusion-positive advanced solid tumors. The IRC assessed ORR was 70.0% (95% CI 50.6–85.3), including 1 CR and 20 PRs, in 30 patients with NTRK fusion-positive advanced solid tumors who received eratrectinib 50 mg BID in Cohort B. The ORR was 60% (204/339, 95% CI 55–65) for larotrectinib5 and 59% (32/54, 95% CI 45–72) for entrectinib [6] in patients with NTRK fusion-positive advanced solid tumors. In this study, 90.5% (95% CI 67.0-97.5) of responding patients remained on response beyond 12 months and 78.0% (95% CI 57.4–89.5) of patients remained progression-free beyond 12 months in Cohort B, with the longest DoR of 38.6 months and PFS of 40.5 months as the data cutoff date of March 19, 2025. For larotrectinib and entrectinib, the proportion of patients with DoR beyond 12 months were 64% and 56%, respectively [5, 6]. It was worth noting that the ORR in Cohort D was 2.6% (1/38; 95% CI 0-13.8), which was considered attributable to the absence of NTRK fusions in these patients (some patients harbored NTRK point mutations), indicating necessity for the accurate detection of NTRK fusions to identify the target patient population of TRK TKIs, at least for eratrectinib. There were some limitations in the phase 1 dose-escalation part and dose-expansion part of this phase 1/2 study. Cautions should be taken in applicating the safety and PK results to other ethnicities or paediatric patients, as only Chinese adult patients were enrolled. The CNS efficacy of eratrectinib needs further investigation due to the limited number of patients with brain metastasis. This study was also limited by the rather small number of patients in a specific tumor type. In conclusion, this study demonstrated manageable safety profile and compelling efficacy of eratrectinib in patients with NTRK fusion-positive solid tumors, representing a promising treatment option for this patient population. Further studies to confirm the efficacy and safety of eratrectinib are ongoing. Conlusions Eratrectinib demonstrated a manageable safety profile and promising efficacy in patients with NTRK fusion-positive solid tumors, including those with prior TRK TKI exposure and confirmed solvent front mutations (G595R/G623R), representing a new treatment option for this patient population. The RP2D of 50 mg BID is well-tolerated with an efficacy plateau and suitable for long-term clinical application. Central laboratory confirmation of NTRK fusions is critical for identifying the target patient population and ensuring the validity of clinical trial results. Further studies with larger sample size, multi-ethnic enrollment, and longer follow-up are ongoing to confirm the efficacy and safety of eratrectinib, including its CNS activity and long-term tolerability. Supplementary Information Below is the link to the electronic supplementary material. Supplementary Material 1. Supplementary Material 1.